# A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors

> **NCT02232620** · PHASE2 · TERMINATED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** BBI503

## Key facts

- **NCT ID:** NCT02232620
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-13
- **Primary completion:** 2017-07-25
- **Final completion:** 2017-07-25
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low feasibility
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02232620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02232620, "A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02232620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*